Michael Higgins
Stock Analyst at Ladenburg Thalmann
(1.79)
# 3,191
Out of 4,944 analysts
21
Total ratings
29.41%
Success rate
5.55%
Average return
Main Sectors:
Stocks Rated by Michael Higgins
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRDN Viridian Therapeutics | Downgrades: Neutral | n/a | $17.97 | - | 4 | May 9, 2024 | |
| FBRX Forte Biosciences | Upgrades: Buy | $69 | $10.77 | +538.35% | 3 | Apr 8, 2024 | |
| OVID Ovid Therapeutics | Reiterates: Buy | $7 | $0.55 | +1,179.71% | 1 | May 2, 2023 | |
| SCYX SCYNEXIS | Reiterates: Buy | $15 | $0.86 | +1,644.39% | 1 | Apr 3, 2023 | |
| ARTL Artelo Biosciences | Reiterates: Buy | $360 | $9.68 | +3,619.01% | 2 | Apr 3, 2023 | |
| RYTM Rhythm Pharmaceuticals | Reiterates: Buy | $35 | $96.39 | -63.69% | 3 | Mar 2, 2023 | |
| PHGE BiomX | Maintains: Buy | $130 → $80 | $0.56 | +14,134.88% | 2 | May 12, 2022 | |
| NVAX Novavax | Downgrades: Sell | $105 | $8.48 | +1,138.21% | 2 | Aug 5, 2020 | |
| VIRT Virtu Financial | Upgrades: Buy | $29 | $42.11 | -31.13% | 2 | Jan 4, 2019 | |
| SVRA Savara | Reinstates: Buy | n/a | $2.58 | - | 1 | Sep 27, 2017 |
Viridian Therapeutics
May 9, 2024
Downgrades: Neutral
Price Target: n/a
Current: $17.97
Upside: -
Forte Biosciences
Apr 8, 2024
Upgrades: Buy
Price Target: $69
Current: $10.77
Upside: +538.35%
Ovid Therapeutics
May 2, 2023
Reiterates: Buy
Price Target: $7
Current: $0.55
Upside: +1,179.71%
SCYNEXIS
Apr 3, 2023
Reiterates: Buy
Price Target: $15
Current: $0.86
Upside: +1,644.39%
Artelo Biosciences
Apr 3, 2023
Reiterates: Buy
Price Target: $360
Current: $9.68
Upside: +3,619.01%
Rhythm Pharmaceuticals
Mar 2, 2023
Reiterates: Buy
Price Target: $35
Current: $96.39
Upside: -63.69%
BiomX
May 12, 2022
Maintains: Buy
Price Target: $130 → $80
Current: $0.56
Upside: +14,134.88%
Novavax
Aug 5, 2020
Downgrades: Sell
Price Target: $105
Current: $8.48
Upside: +1,138.21%
Virtu Financial
Jan 4, 2019
Upgrades: Buy
Price Target: $29
Current: $42.11
Upside: -31.13%
Savara
Sep 27, 2017
Reinstates: Buy
Price Target: n/a
Current: $2.58
Upside: -